Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
Narrative review for orthopaedic physicians noting tesamorelin is approved for HIV-associated lipodystrophy but has no orthopaedic evidence.
- Tesamorelin, approved for treating HIV-associated lipodystrophy, has no supporting orthopaedic evidence
- Indications, dosing, frequency and duration of treatment for these peptides remain unknown
- Significant safety and efficacy research is needed before definitive recommendations can be made to patients
Compound: Tesamorelin Citation: Mayfield CK, Bolia IK, Feingold CL, Lin EH, Liu JN, Rick Hatch GF, Gamradt SC, Weber AE. Am J Sports Med. 2026;54(1):223-229. doi: 10.1177/03635465251357593. PubMed
Summary
Narrative review, not a tesamorelin study, written as a primer for orthopaedic surgeons and sports medicine physicians on popular injectable peptides: BPC-157, TB-4, TB-500, CJC-1295 + ipamorelin, tesamorelin and GHK-Cu. For tesamorelin, the authors note it is approved for treating HIV-associated lipodystrophy but has no supporting orthopaedic evidence.
Key Findings
- Tesamorelin is approved for HIV-associated lipodystrophy; the review found no supporting orthopaedic evidence for it
- Across the peptides reviewed, the indications, dosing, frequency and duration of treatment remain unknown
- The authors call for significant safety and efficacy research before definitive recommendations can be made to patients
See Also
- Parent compound: Tesamorelin
Save 10% with code aewpzbzd
VialBase may earn a commission on partner links — never at extra cost to you. Disclosure.